Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Moderna slips
Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.
Moderna slips as Goldman Sachs downgrades on revenue outlook
Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Read more here.
Moderna downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance
Moderna Stock Falls on Vaccine Revenue Concerns
Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price target from $99 to $51, citing ongoing vaccine revenue challenges.
S&P 500 Gains and Losses Today: Moderna Stock Plunges After Analyst Downgrade
The S&P 500 fell 0.5% on Wednesday, Jan. 29, as the Federal Reserve held interest rates steady in a move widely expected by the financial markets.
2d
Moderna Stock Is Sliding Wednesday: Here's Why
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
1d
on MSN
Why Moderna (MRNA) Crashed on Wednesday?
We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...
12h
Moderna (MRNA) Receives a Hold from Bernstein
In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...
Wall Street Journal
10d
Goldman Sachs Promotes Its Next Generation of Leaders
Goldman
Sachs
GS0.71%increase; green up pointing triangle announced a number of promotions in its global banking and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback